ClinicalTrials.gg
CompletedNCT03034057Updated Oct 18, 2019Results posted

Sayana Press UK Self-Injection Study

A Phase 4 interventional study of Sayana Press in Contraception, sponsored by Pfizer. Completed at 28 sites in United Kingdom. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-18.

Sponsored by Pfizer · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
169
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

A one-year evaluation of Sayana Press self injection in women of reproductive age in the United Kingdom (UK).

02

Conditions studied

  • Contraception
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women aged 18 to 45 years of age who are willing to attempt Sayana Press self-injection at home;
  • women who are likely to be successful on a DMPA self-injection program, based on the opinion of the investigator;
  • not planning to move out of the area for at least 12 months;
  • willing to be contacted by the clinical staff at work or at home;
  • evidence of a personally signed and dated Document (ICD) indicating that the subject has been informed of all pertinent aspects of the study;
  • subjects who are willing and able to comply with scheduled visits, treatment plan and other study procedures

Exclusion criteria

Exclusion Criteria:

  • a pre-existing medical condition that would interfere with participation in the study or pose a risk to the subject, including to MPA or any constituents of Sayana Press;
  • known or suspected of genital organs;
  • known or suspected malignancy of the breast;
  • history of cerebrovascular disease
  • metabolic bone disease
  • a to DMPA (UK Medical Eligibility Criteria Category 3 or 4) such as:
  • Multiple risk factors for cardiovascular disease (e.g. older age, smoking, diabetes, obesity, hypertension)
  • current and history of ischaemic heart disease;
  • stroke (history of cerebrovascular accident, including );
  • unexplained vaginal bleeding;
  • current or history of breast cancer;
  • diabetic nephropathy, neuropathy, retinopathy or other diabetic vascular disease;
  • severe (decompensated) liver cirrhosis;
  • hepatocellular adenoma;
  • hepatoma;
  • Systemic Lupus Erythematosus (positive or unknown antiphospholipid antibodies; severe thrombocytopenia;
  • subjects who are centre staff members directly involved in the conduct of the study and their family members, centre staff members otherwise supervised by the investigator, or subjects who are Pfizer employees involved in the conduct of the study;
  • participation in other studies involving investigational drug(s) within 30 days prior to study entry and/or during study participation;
  • patients who plan to get pregnant within two years of study;
  • breastfeeding and pregnant subjects;
  • other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgement of the investigator, would make the subject inappropriate for entry into this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
169 participants (actual)

Study arms

  • Other
    sayana press

    single arm

    Drug: Sayana Press

Interventions

  • Sayana Press in the Uniject injection system

06

What researchers measure

Primary outcomes

  1. Percentage of Successful Self-Injections Performed of All Attempts at Home on Schedule (Full Analysis Set)

    Each participant had a maximum of 3 home self-injections, each of which was defined as a success or failure. A success was defined as a home self-injection that was successfully performed by the participant at home and on schedule (13 week interval +/- 1 week) where all attempts were included in the denominator. If the participant attempted but was unable to administer the self-injection at home and had it performed instead at the clinic, then these were classed as failures. This outcome measure was analyzed by generalized estimating equation (GEE) model using participant as the clustering variable. The GEE model used the logit link and contained an intercept term. The 95% confidence interval (CI) for the intercept was transformed to a 95% CI for the self-injection success rate.

    Time frame: Up to 1 year

  2. Percentage of Successful Self-Injections Performed of All Attempts at Home on Schedule (Sensitivity Analysis)

    Each participant had a maximum of 3 home self-injections, each of which was defined as a success or failure. A success was defined as a home self-injection that was successfully performed by the participant at home and on schedule (13 week interval +/- 1 week) where all attempts were included in the denominator. If the participant attempted but was unable to administer the self-injection at home and had it performed instead at the clinic, then these were classed as failures. This outcome measure was analyzed by GEE model using participant as the clustering variable. The GEE model used the logit link and contained an intercept term. The 95% CI for the intercept was transformed to a 95% CI for the self-injection success rate. The sensitivity analysis was conducted to eliminate the data from the discontinued site due to ongoing Good Clinical Practice (GCP) violations.

    Time frame: Up to 1 year

Secondary outcomes

  1. Continuation Rate for the Method (Self-injection With Sayana Press) at 1 Year

    Continuation rate for the method at 1 year equals: (\[the number of participants who received all 4 injections and had not discontinued by 12 months\] / \[total number of participants in the study\]) \*100%. A 95% CI was calculated along with the continuation rate using normal approximation to the binominal.

    Time frame: 1 year

07

Results

Posted Oct 18, 2019

Participant flow

Participant flow — Overall Study
MilestoneSayana Press
Started169
Completed114
Not completed55
Withdrew: Withdrawal by subject10
Withdrew: Protocol violation1
Withdrew: Not defined2
Withdrew: Lost to follow-up19
Withdrew: Adverse event22
Withdrew: Medication error without associated ae1

Outcome measures

PrimaryPercentage of Successful Self-Injections Performed of All Attempts at Home on Schedule (Full Analysis Set)

Each participant had a maximum of 3 home self-injections, each of which was defined as a success or failure. A success was defined as a home self-injection that was successfully performed by the participant at home and on schedule (13 week interval +/- 1 week) where all attempts were included in the denominator. If the participant attempted but was unable to administer the self-injection at home and had it performed instead at the clinic, then these were classed as failures. This outcome measure was analyzed by generalized estimating equation (GEE) model using participant as the clustering variable. The GEE model used the logit link and contained an intercept term. The 95% confidence interval (CI) for the intercept was transformed to a 95% CI for the self-injection success rate.

Time frame:
Up to 1 year
Reported as:
Number · Percentage of all attempts at home
Percentage of Successful Self-Injections Performed of All Attempts at Home on Schedule (Full Analysis Set)
Percentage of all attempts at homeSayana Press
Percentage of Successful Self-Injections Performed of All Attempts at Home on Schedule (Full Analysis Set)88.8 (85.1 to 91.6)
PrimaryPercentage of Successful Self-Injections Performed of All Attempts at Home on Schedule (Sensitivity Analysis)

Each participant had a maximum of 3 home self-injections, each of which was defined as a success or failure. A success was defined as a home self-injection that was successfully performed by the participant at home and on schedule (13 week interval +/- 1 week) where all attempts were included in the denominator. If the participant attempted but was unable to administer the self-injection at home and had it performed instead at the clinic, then these were classed as failures. This outcome measure was analyzed by GEE model using participant as the clustering variable. The GEE model used the logit link and contained an intercept term. The 95% CI for the intercept was transformed to a 95% CI for the self-injection success rate. The sensitivity analysis was conducted to eliminate the data from the discontinued site due to ongoing Good Clinical Practice (GCP) violations.

Time frame:
Up to 1 year
Reported as:
Number · Percentage of all attempts at home
Percentage of Successful Self-Injections Performed of All Attempts at Home on Schedule (Sensitivity Analysis)
Percentage of all attempts at homeSayana Press
Percentage of Successful Self-Injections Performed of All Attempts at Home on Schedule (Sensitivity Analysis)89.3 (85.6 to 92.1)
SecondaryContinuation Rate for the Method (Self-injection With Sayana Press) at 1 Year

Continuation rate for the method at 1 year equals: (\[the number of participants who received all 4 injections and had not discontinued by 12 months\] / \[total number of participants in the study\]) \*100%. A 95% CI was calculated along with the continuation rate using normal approximation to the binominal.

Time frame:
1 year
Reported as:
Number · Percentage of total participants
Continuation Rate for the Method (Self-injection With Sayana Press) at 1 Year
Percentage of total participantsSayana Press
Continuation Rate for the Method (Self-injection With Sayana Press) at 1 Year67.5 (59.8 to 74.5)

Adverse events

Collected over Up to 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sayana Press0/169 (0%)5/169 (3%)60/169 (35.5%)
Most frequent serious events
Most frequent serious events
EventSayana Press
Food poisoningGastrointestinal disorders1/169
MastitisInfections and infestations1/169
Ovarian germ cell teratoma benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/169
Cauda equina syndromeNervous system disorders1/169
Cervical dysplasiaReproductive system and breast disorders1/169
Most frequent other events
Most frequent other events
EventSayana Press
Injection site bruisingGeneral disorders22/169
Vaginal haemorrhageReproductive system and breast disorders21/169
DepressionPsychiatric disorders13/169
Injection site painGeneral disorders11/169
Injection site massGeneral disorders9/169

Baseline characteristics

Baseline analysis population included all participants who enrolled into the study.

Age, Continuous
Age, Continuous(Years)Sayana Press
Mean29.1 ± 7.26
Sex: Female, Male
Sex: Female, Male(Participants)Sayana Press
Female169
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sayana Press
Hispanic or Latino0
Not Hispanic or Latino154
Unknown or Not Reported15
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sayana Press
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American5
White163
More than one race0
Unknown or Not Reported1
08

Study locations

28 sites
  • Fowey Clinical Research Office
    Fowey, Cornwall PL23 1DT, United Kingdom
  • Fowey River Practice
    Fowey, Cornwall PL23 1DT, United Kingdom
  • Brannel Surgery
    Saint Austell, Cornwall PL26 7RL, United Kingdom
  • Rame Medical Ltd, Penntorr Health
    Torpoint, Cornwall PL11 2TB, United Kingdom
  • Rame Medical Ltd
    Torpoint, Cornwall PL11 2TB, United Kingdom
  • Knowle House Surgery
    Plymouth, Devon PL5 3JB, United Kingdom
  • NHS Ayrshire & Arran, University Hospital Crosshouse
    Kilmarnock, EAST Ayrshire KA2 0BE, United Kingdom
  • Trafalgar Medical Group Practice
    Southsea, Hampshire PO5 3ND, United Kingdom
  • NHS Highland Clinical Research Facility
    Inverness, Highland IV2 3JH, United Kingdom
  • Kent Community Health NHS Foundation Trust
    Canterbury, Kent CT1 3NG, United Kingdom
  • Kent Community Health NHS Foundation Trust
    Chatham, Kent ME4 4DT, United Kingdom
  • Southport & Ormskirk Hospital NHS Trust, The May Logan Healthy Living Centre
    Liverpool, Merseyside L205DQ, United Kingdom
  • Southport & Ormskirk Hospital NHS Trust
    Liverpool, Merseyside L205DQ, United Kingdom
  • NHS Lothian, Chalmers Sexual Health Centre
    Edinburgh, Midlothian EH3 9ES, United Kingdom
  • NHS Ayrshire & Arran, Ayrshire Central Hospital
    Irvine, North Ayrshire KA 12 8SS, United Kingdom
  • Pickering Medical Practice
    Pickering, North Yorkshire YO18 8BL, United Kingdom
  • St Chad's Surgery
    Radstock, Somerset BA32UH, United Kingdom
  • The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Newcastle upon Tyne, Tyne and Wear NE1 4LP, United Kingdom
  • The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Newcastle upon Tyne, Tyne and Wear NE1 6ND, United Kingdom
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, WEST Midlands B15 2TH, United Kingdom
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, WEST Midlands B4 6DH, United Kingdom
  • Eve Hill Medical Practice
    Dudley, WEST Midlands DY1 2QD, United Kingdom
  • Bradford on Avon Health Centre
    Bradford on Avon, Wiltshire BA15 1DQ, United Kingdom
  • Hathaway Medical Centre
    Chippenham, Wiltshire SN14 6GT, United Kingdom
  • Trowbridge Health Centre
    Trowbridge, Wiltshire BA148QA, United Kingdom
  • Westbury Group Practice
    Westbury, Wiltshire BA13 3FQ, United Kingdom
  • CPS Research
    Glasgow, G20 0XA, United Kingdom
  • Homerton University Hospital NHS Foundation Trust, Homerton
    London, E9 6SR, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Dec 2018, 15 months.

Results were first posted in Oct 2019, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2017
First posted
Jan 27, 2017
StartActual
Aug 23, 2017
Primary completionActual
Dec 7, 2018
CompletionActual
Dec 7, 2018
Results first posted
Oct 18, 2019
Last update
Oct 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03034057
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 27, 2017
Start date
Aug 23, 2017
Primary completion
Dec 7, 2018
Completion
Dec 7, 2018
Results posted
Oct 18, 2019
Last update
Oct 18, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Medroxyprogesterone Acetate

Start the discussion